Journal of Clinical Oncology - ASCO Publications
Oct 31, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or ...
Current and Future Management of HER2-Positive Metastatic …
Jun 2, 2021 · Advanced breast cancer with overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) is a clinically aggressive subtype with poor survival outcomes. 1,2 However, with the introduction of trastuzumab, the survival rates have greatly improved. 1 Trastuzumab binds to the extracellular domain IV of HER2 preventing its activation. 3 In addition, other mechanisms have ...
Management of Immune-Related Adverse Events in Patients …
Immunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize and attack cancer ...
When a Monoclonal Gammopathy Is Not Multiple Myeloma
Apr 8, 2022 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority of MGUS cases arise from a malignant ...
Evidence-Based Management of Oral Mucositis | JCO Oncology …
Feb 3, 2020 · The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy. Historically, management was focused mainly on pain control and nutritional support. However, evidence-based clinical practice guidelines for oral and GI mucositis were recently updated.
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Guidelines can address specific clinical situations (disease-oriented) or use of approved medical products, procedures, or tests (modality-oriented). Using the best available evidence, ASCO expert panels identify and develop practice recommendations for specific areas of cancer care that would benefit from the availability of practice guidelines.
Advances in Breast Cancer Radiotherapy: Implications for Current …
Oct 15, 2021 · As previously mentioned, the randomized trials that demonstrated the safety and efficacy of breast-conserving therapy used adjuvant WBI. However, over the past three decades, more than seven prospective randomized trials have compared WBI with more targeted forms of radiation (ie, partial breast irradiation [PBI]), demonstrating no statistically significant differences in local recurrence in ...
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Oct 17, 2022 · Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Managing Metastatic Melanoma in 2022: A Clinical Review
The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine protein kinase that was described in 1983 as an oncogene playing a critical role in the RAS-RAF-MEK-ERK mitogen–activated protein kinase (MAPK) cell signaling pathway, with high frequencies of BRAF point mutations discovered in melanoma and other human cancers. 6,7 The activating BRAF mutations observed in 37%-53 ...
Estrogen and Progesterone Receptor Testing in Breast Cancer: …
Jan 13, 2020 · First released in 2010, the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) estrogen receptor (ER) and progesterone receptor (PgR) testing guideline is aimed at improving the analytic performance and diagnostic accuracy of ER and PgR testing and their clinical utility as biomarkers for the management of women with primary breast cancer. 1,2 The guideline ...